{
    "clinical_study": {
        "@rank": "56855", 
        "arm_group": {
            "arm_group_label": "122-0551", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Adrenal suppression effects of corticosteroids are among the most important safety concerns\n      for this group of products. This study is designed to determine the adrenal effects of the\n      investigational formulation of 122-0551 and characterize the steady state pharmacokinetics\n      of the formulation."
        }, 
        "brief_title": "Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a clinical diagnosis of stable plaque psoriasis\n\n        Exclusion Criteria:\n\n          -  Subject has spontaneously improving or rapidly deteriorating plaque psoriasis\n\n          -  Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis\n\n          -  Subject has used any phototherapy, photo-chemotherapy or systemic psoriasis therapy\n             within 30 days prior to initiation of treatment\n\n          -  Subject has used systemic corticosteroids or topical, inhaled, intranasal\n             corticosteroids within 30 days and 14 days, respectively, prior to study screening\n\n          -  Subject has had prolonged exposure to natural or artificial sources of ultraviolet\n             radiation within 30 days prior to initiation of treatment\n\n          -  Subject has used topical psoriatic therapy including tar, anthralin, retinoids,\n             vitamin D analogs (e.g., Dovonex\u00ae) within 14 days prior to  initiation of treatment\n\n          -  Subject has used emollients/moisturizers on areas to be treated within one day prior\n             to initiation of treatment\n\n          -  Subject is currently using lithium or Plaquenil (hydroxychloroquine)\n\n          -  Subject is currently using a beta-blocking medication (e.g., propanolol) or\n             angiotensin converting enzyme (ACE) inhibitors (e.g., lisinopril) at a dose that has\n             not been stabilized\n\n          -  Subject is pregnant, nursing or planning a pregnancy during the study period\n\n          -  Subject is currently enrolled in an investigational drug, biologic or device study\n\n          -  Subject has received an investigational drug, biologic or an investigational device\n             within 30 days prior to study start\n\n          -  Subject has been previously enrolled in this study and treated with the test article\n\n          -  Subject has an irregular sleep schedule or works night shifts"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698333", 
            "org_study_id": "122-0551-202"
        }, 
        "intervention": {
            "arm_group_label": "122-0551", 
            "description": "Applied twice daily for 2 weeks", 
            "intervention_name": "122-0551", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "122-0551", 
            "steroid", 
            "HPA"
        ], 
        "lastchanged_date": "November 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Anaheim Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "Therapeutics Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78759"
                    }, 
                    "name": "DermResearch, Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment", 
        "overall_official": {
            "affiliation": "Therapeutics, Inc.", 
            "last_name": "Syd Dromgoole, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "HPA axis response to stimulation by cosyntropin, dichotomized to \"normal\" and \"abnormal\". An abnormal HPA axis response is defined as a 30-minute post-stimulation serum cortisol level that is \u2264 18 \u03bcg/dL at the end of study.", 
            "measure": "Hypothalamic-Pituitary-Adrenal (HPA) axis response", 
            "safety_issue": "No", 
            "time_frame": "Day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698333"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}